TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06093386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Transition Support
Description: Participants assigned to the intervention arm will transfer their transition support leadership to a transition team composed of a transition navigator (an advance practice nurse), a nurse navigator (a registered nurse) and a social worker over 2 years to support them through the multiple phases of CMC transitions including guidance, monitoring, planning, care transfer and transfer completion. CMC and their caregivers will be offered support in care planning, receiving funding, and connecting with a primary care provider and adult subspecialists.
Study: NCT06523114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Arterial Embolization
Description: After accessing the common femoral artery or radial artery, embolization is performed using embolic material after confirming abnormal blood vessel abnormalities, lesion hypervascularity, and lesion enhancement findings.
Study: NCT05212857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: Given subcutaneously or as an injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: Given subcutaneously or as an injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate
Description: Given subcutaneously or as an injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix acetate
Description: Given subcutaneously or as an injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local treatment for primary lesion
Description: Radical prostatectomy to remove prostate primary lesion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy for primary lesion
Description: Radical radiotherapy for primary lesion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy for metastatic lesion
Description: Stereotactic body radiation therapy or proton and heavy ion radiation therapy is preferred, which could treat all the lesions at once or treat different lesions in stages.
Study: NCT05401396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swimming immediately after eating
Description: After having the last bite of lunch, the participants will swim in the pool with a specific distance.
Study: NCT04860908

Intervention type: OTHER
Intervention: no intervention, observation only
Description: no intervention, observation only

Intervention type: OTHER
Intervention: no intervention, observation only
Description: no intervention, observation only
Study: NCT05419661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operational Pre-Planning
Description: Using a 3D printer, printing of the patient's aneurysm from the segmented 3D images obtained during the initial assessment and thus allowing a simulation of the embolization procedure. This pre-operative planning (PPO) carried out in real conditions aims to anticipate the possible complications that could be encountered on the same day of treatment.
Study: NCT06107192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention - apple catechin diet
Description: The intervention will provide a catechin-containing apple juice, for consumption alongside a low catechin diet tailored to participants calorie needs for weight maintenance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary intervention - low catechin diet
Description: The intervention will provide a nutritionally-matched beverage without catechins, for consumption alongside a low catechin diet tailored to participants calorie needs for weight maintenance.
Study: NCT06398743

Intervention type: DEVICE
Intervention: MRD
Description: ctDNA MRD test
Study: NCT05525078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-cigarette
Description: Participants will select a Target Switch on which they will stop smoking cigarettes and switch entirely to the e-cigarette product.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch, Nicotine lozenge
Description: Participants will select a Target Quit Date on which they will stop smoking, using the patches and lozenges provided.
Study: NCT06491966

Intervention type: OTHER
Intervention: observation
Description: data collected includes demographic information, clinical outcomes (mortality rate, ICU stay length), inflammatory markers (e.g., IL-2, IL-10, TNF-α), and treatment details (mechanical ventilation, CRRT, ECMO, antibiotics). Culture results, NGS findings, and imaging reports were also documented.

Intervention type: OTHER
Intervention: observation
Description: data collected includes demographic information, clinical outcomes (mortality rate, ICU stay length), inflammatory markers (e.g., IL-2, IL-10, TNF-α), and treatment details (mechanical ventilation, CRRT, ECMO, antibiotics). Culture results, NGS findings, and imaging reports were also documented.
Study: NCT04762901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Injection
Study: NCT05836545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: The patient with remimazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: The patient with midazolam
Study: NCT05783505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention program
Description: Non-pharmacological interventions combined with goal directed sedation using dexmedetomidine if needed
Study: NCT04678882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
Study: NCT05696938

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wonderlab Nicotinamide Drink
Description: Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ordinary Drink
Description: Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
Study: NCT05162157

Intervention type: DEVICE
Intervention: NuvoAir platform
Description: Nuvoair platform, consisting of a bluetooth spirometer, smartphone application and clinical portal
Study: NCT06027801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron-fortified cookies
Description: Study cookies fortified with ferrous fumarate, providing 15 mg of elemental iron in each portion.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Japanese encephalitis (JE) vaccine
Description: All participants will be administered the live attenuated JE vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis (JE) vaccine
Description: All participants will be administered the live attenuated JE vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Typhoid Vi polysaccharide (Vi-PS) vaccine
Description: All participants will be administered the typhoid Vi-PS vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid Vi polysaccharide (Vi-PS) vaccine
Description: All participants will be administered the typhoid Vi-PS vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-fortified cookies
Description: Study cookies containing no iron
Study: NCT04762901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV
Study: NCT05245448

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetrandrine
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrandrine
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT05694143

Intervention type: OTHER
Group type: OTHER
Intervention: Education Intervention
Description: This intervention is based on the Health Belief Model Theory, which examines the attitudes and beliefs of adolescents with enhanced knowledge and perceived disease risk. As a result, It aims to build on adolescents' skills and behaviours rather than increase their knowledge, beliefs, and relative skills. In order to develop the education program, health promotion experts with a special interest in changing obesity-related behaviours will assist the researcher.~The intervention is specifically designed to help adolescents:~* To know facts, statistics and harmful effects of obesity and overweight.~* To know facts about physical activity and its importance.~* To know facts about a healthy diet and its importance.~* Definition of BMI and calculating the BMI.~* To read the Nutrition Facts label.~* To develop decision-making and self-care education.

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: They will have their regular curriculums and normal physical activity routine
Study: NCT05792657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High dosage in-person exercise coaching
Description: High dosage (one hour each week) of in-person exercise coaching by an exercise professional.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medium dosage in-person exercise coaching.
Description: Medium dosage (one hour every other week) of in-person exercise coaching by an exercise professional.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dosage in-person exercise coaching
Description: Low dosage (one hour every month) of in-person exercise coaching by an exercise professional
Study: NCT05883670

Intervention type: DRUG
Intervention: Serplulimab
Description: Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Study: NCT06154278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imdusiran (AB-729)
Description: 60mg subcutaneously, every 8 weeks, for a total of 4 doses
Study: NCT05164107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Globe Mapping and Pulsed Field Ablation System (Globe PF System)
Description: During the procedure, the Globe Catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the left atrium (LA) will be followed by pulsed field ablation (PFA) to achieve pulmonary vein isolation (PVI). Additional PFA or radiofrequency (RF) ablation lesions may be created as deemed appropriate by the Investigator. Intracardiac electrogram mapping with the Globe PF System will be used to confirm PVI.
Study: NCT05769725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab, 4.5mg/kg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S1
Description: Tegafur-gimeracil-oteracil potassium: 50mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: Tegafur-gimeracil-oteracil potassium: 50mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
Study: NCT05132933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP trial - Electrical Impedance Tomography
Description: Three different levels of PEEP and two different levels of FiO2 will be tested without changing anything else in the baseline patient ventilation
Study: NCT05853666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CNH+
Description: CNH+ is a bundled intervention targeting all four of Bandura's factors associated with improved self-efficacy (i.e., Mastery \[evidence-based parent targeted education platform\]; Vicarious Experience \[observing other families similar to them succeeding in a task i.e., videos and photos\]; Verbal Persuasion \[in-person/virtual medical rounds and provision of social support\]; and Physiological States \[notifications and encouragement through mHealth text messaging, parent feedback, and tailored clinical care pathway\]).
Study: NCT05228626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVIDEX
Description: COVIDEXTm is a prepared plant extract of Zanthoxylum and Warbugia species that is reported to have antiviral agents, one of which berberine with in vitro activity against SARS COV-2, the causative agent for COVID-19 disease. Others constituents in COVIDEX include alkaloids, sponins, reducing sugars and acidic compounds. IT is given either 2 drops nasally plus 6 drops orally or 6 oral drops only of COVIDEXTm three times daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: COVIDEX
Description: COVIDEXTm is a prepared plant extract of Zanthoxylum and Warbugia species that is reported to have antiviral agents, one of which berberine with in vitro activity against SARS COV-2, the causative agent for COVID-19 disease. Others constituents in COVIDEX include alkaloids, sponins, reducing sugars and acidic compounds. IT is given either 2 drops nasally plus 6 drops orally or 6 oral drops only of COVIDEXTm three times daily for 7 days.
Study: NCT05403684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-volume breastmilk
Description: Preterm infants will be given high-volume breastmilk
Study: NCT06054425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Infusion; intravenous
Study: NCT04887766

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GS300
Description: Gelesis300 hydrogel in gelatin capsules

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT05552833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Participants will undergo 12 weeks of supervised HIIT training (3 times per week). The HIIT protocol will consist of 4x4 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Participants will undergo 12 weeks of supervised HIIT training (3 times per week). The HIIT protocol will consist of 4x4 min.
Study: NCT05479487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib+Apatinib
Description: Fluzoparib 100mg bid+ Apatinib 375mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzoparib Monotherapy
Description: Fluzoparib 150mg bid
Study: NCT04943029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab
Description: Camrelizumab: 200mg, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 3 cycles; Adjuvant therapy: 16cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)
Description: Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles; Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 3 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery must be done within the 4th-6th week from day 1 cycle 3 of neoadjuvant treatment (4-6 weeks after day 1 of cycle 3)
Study: NCT04552418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potato starch
Description: Starting 5-7 days before treatment with dual-ICI, participant will consume 20g of potato starch (Bob's Red Mill®) once a day for 3 days, then increase to 20g twice a day, continuing throughout dual-ICI treatment (total duration approximately 13 weeks).
Study: NCT05952986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB825 or Placebo in subcutaneous route
Description: FB825 or placebo solution for SC injection
Study: NCT05985993

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low-intensity transcranial ultrasound stimulation (TUS)
Description: The rTUS was administered using an immersion-type focused ultrasound transducer (V391-SU, Olympus NDT, Waltham, USA). Low-intensity transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low-intensity transcranial ultrasound stimulation (TUS)
Description: The rTUS was administered using an immersion-type focused ultrasound transducer (V391-SU, Olympus NDT, Waltham, USA). Low-intensity transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low-intensity transcranial ultrasound stimulation (TUS)
Description: The rTUS was administered using an immersion-type focused ultrasound transducer (V391-SU, Olympus NDT, Waltham, USA). Low-intensity transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).
Study: NCT05952986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB825 or Placebo in subcutaneous route
Description: FB825 or placebo solution for SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB825 in intravenous route
Description: FB825 solution for IV infusion
Study: NCT04052139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose naltrexone
Description: 4.5 mg of low dose naltrexone taken once daily for 8 weeks. In week 1, participants will take 4.5mg of naltrexone once daily. In week 2, participants will take 4.5mg of naltrexone once daily, and a placebo capsule twice daily. In weeks 3 through 7, participants will take 1 placebo capsule with 4.5 mg mg of naltrexone once daily, and 2 placebo capsules twice daily. In week 8, in days 1-4 participants will take 4.5 mg of naltrexone with a placebo capsule once daily and 2 placebo capsules twice daily; in days 5-7, participants will take 4.5 mg of naltrexone once daily, and a placebo capsule twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Dose will begin at 300 mg daily (300 mg qd), in week 2 the dose will be titrated up to 900 mg daily (300 mg tid). In week 3, the dose will be titrated to 1800 mg daily ( 2 capsules of 300 mg tid) and participants will remain on that dose until week 8. In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In week 1, participants will take 1 placebo capsule once daily. In week 2, participants will take 1 placebo capsule three times per day. In weeks 3 through 7, 2 placebo capsules three times per day. In week 8, in days 1-4 participants will take 2 placebo capsules three times per day; in days 5-7, participants will take 1 placebo capsule three times per day. The placebo medications will be composed of lactose and will not contain active ingredients.
Study: NCT06054425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risankizumab
Description: Infusion; intravenous
Study: NCT05624710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: INCB054707 75 mg will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: INCB054707 75 mg will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: INCB054707 75 mg will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: INCB054707 75 mg will be administered orally on Day 1.
Study: NCT05579171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosecond 755nm Alexandrite Laser
Description: Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
Study: NCT06162455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham treatment
Description: Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200- ppm NO
Description: NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min